Last reviewed · How we verify

NCT04999930

Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)

Completed NA Last updated 18 August 2021
What this trial tests

NA trial testing Aerochamber in Chronic Obstructive Pulmonary Disease in 100 participants. Completed in 28 February 2021.

Timeline
10 January 2020
Primary endpoint
28 February 2021
28 February 2021

Quick facts

Lead sponsorNational University of Malaysia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment100
Start date10 January 2020
Primary completion28 February 2021
Estimated completion28 February 2021
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

National University of Malaysia

Who can join

40 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COPD patient on Tiotropium Respimart divided into two group, Group A given aerochamber and Group B without aerochamber enroll in the study for total 18 week .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other National University of Malaysia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing